Immunome (IMNM) Projected to Release Earnings on Wednesday

Immunome (NASDAQ:IMNM) is projected to post its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.5138) per share and revenue of $0.1670 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.12. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Immunome Stock Up 1.1%

Shares of NASDAQ IMNM opened at $23.01 on Tuesday. The business’s 50 day moving average is $21.23 and its two-hundred day moving average is $22.07. The company has a market cap of $2.61 billion, a P/E ratio of -9.67 and a beta of 2.07. Immunome has a 12 month low of $8.66 and a 12 month high of $27.65.

Insider Activity

In other Immunome news, CFO Max Rosett sold 60,000 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $18.23, for a total value of $1,093,800.00. Following the transaction, the chief financial officer directly owned 54,037 shares in the company, valued at $985,094.51. The trade was a 52.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 1,092 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $25.00, for a total transaction of $27,300.00. Following the sale, the insider directly owned 1,092 shares of the company’s stock, valued at approximately $27,300. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 472,142 shares of company stock valued at $10,262,648. 7.21% of the stock is owned by company insiders.

Institutional Investors Weigh In On Immunome

A number of large investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. increased its holdings in Immunome by 59.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after purchasing an additional 5,003,824 shares in the last quarter. Invesco Ltd. boosted its stake in Immunome by 382.1% in the fourth quarter. Invesco Ltd. now owns 270,065 shares of the company’s stock worth $5,801,000 after purchasing an additional 214,049 shares in the last quarter. Virtus Investment Advisers LLC boosted its stake in Immunome by 16.9% in the fourth quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock worth $292,000 after purchasing an additional 1,970 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Immunome by 267.8% during the fourth quarter. Wellington Management Group LLP now owns 934,463 shares of the company’s stock worth $20,072,000 after purchasing an additional 680,395 shares during the last quarter. Finally, SummitTX Capital L.P. bought a new stake in shares of Immunome during the fourth quarter worth $2,741,000. 44.58% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IMNM. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. Leerink Partners reduced their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. Citigroup restated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Barclays assumed coverage on shares of Immunome in a report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price objective on the stock. Finally, Truist Financial upped their price objective on shares of Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Thirteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.